BeiGene Ltd.688235.CG

Why is BeiGene (688235.CG) moving?

Q3 202620 Jun – 13 Aug 2026

▲4

BeiGene Q3: BRUKINSA Soars, First Profit, US Expansion

BRUKINSA Sales and Survival Data BRUKINSA sales hit $3.9 billion, and Phase 3 trials showed survival benefits in two blood cancers. This strong performance drove revenue and profit growth, boosting investor confidence.
This is the core driver of BeiGene's financial performance and stock price.
First Full-Year Profit and Raised Guidance BeiGene achieved its first full-year profit, with first-half net profit up 627% and Q2 revenue up 30%. Management raised full-year guidance, signaling confidence in continued growth.
Profitability milestone and raised guidance are key positive catalysts for the stock.
US Manufacturing Expansion to Mitigate Tariffs A $300 million US manufacturing expansion should help mitigate potential 100% US import tariffs by enabling local production, reducing regulatory and trade risks.
Addresses a major risk factor and supports long-term US market access.
New Collaboration with Revolution Medicines A new collaboration with Revolution Medicines adds pipeline potential, diversifying future growth beyond BRUKINSA and enhancing long-term prospects.
Expands pipeline and reduces reliance on a single product.

August 20265 Aug – 13 Aug 2026

▲4

BeiGene Profit Surges 627%, Guidance Raised on BRUKINSA Strength

First-Half Profit Jumps 627%, Full-Year Revenue Guidance Raised BeiGene's first-half net profit rose 627% to 3.27 billion yuan, with revenue up 26.8% to 22.22 billion yuan. The company raised its 2026 revenue forecast to 44.9–46.2 billion yuan, signaling stronger-than-expected demand for its drugs and boosting investor confidence.
This is the core new financial result that directly drives the stock higher by showing accelerating profitability and raised outlook.
Q2 Revenue Up 30%, BRUKINSA Sales Exceed $1.2 Billion BeiGene's subsidiary BeOne Medicines reported Q2 revenue of $1.7 billion, up 30%, with BRUKINSA global sales exceeding $1.2 billion. The company raised its 2026 revenue guidance by $300 million and operating income guidance by $250 million, reflecting strong global demand.
This provides a more recent quarterly update that reinforces the growth trajectory and raises full-year targets, directly supporting the stock price.
Sector-Wide Rally in Innovative Drugs Lifts BeiGene China's pharmaceutical sector has been rallying, with multiple stocks hitting daily limit-ups. Analysts say this rally may be more durable than previous ones, driven by strong interim results and global expansion. BeiGene's positive results contribute to the sector resonance, attracting capital inflows.
This explains the broader market sentiment and capital rotation into pharma that is lifting BeiGene's stock alongside its own strong results.
New Collaboration with Revolution Medicines Adds Pipeline Potential On August 10, BeiGene announced a collaboration with Revolution Medicines, part of a wave of Chinese pharma global expansion deals. This partnership could bring new pipeline assets and validates BeiGene's research capabilities, offering a potential future growth driver.
This is a new strategic development that could enhance BeiGene's long-term pipeline and global reach, positively impacting investor sentiment.

Latest5 Aug – 13 Aug 2026

▲4

BeiGene Profit Surges 627%, Guidance Raised on BRUKINSA Strength

First-Half Profit Jumps 627%, Full-Year Revenue Guidance Raised BeiGene's first-half net profit rose 627% to 3.27 billion yuan, with revenue up 26.8% to 22.22 billion yuan. The company raised its 2026 revenue forecast to 44.9–46.2 billion yuan, signaling stronger-than-expected demand for its drugs and boosting investor confidence.
This is the core new financial result that directly drives the stock higher by showing accelerating profitability and raised outlook.
Q2 Revenue Up 30%, BRUKINSA Sales Exceed $1.2 Billion BeiGene's subsidiary BeOne Medicines reported Q2 revenue of $1.7 billion, up 30%, with BRUKINSA global sales exceeding $1.2 billion. The company raised its 2026 revenue guidance by $300 million and operating income guidance by $250 million, reflecting strong global demand.
This provides a more recent quarterly update that reinforces the growth trajectory and raises full-year targets, directly supporting the stock price.
Sector-Wide Rally in Innovative Drugs Lifts BeiGene China's pharmaceutical sector has been rallying, with multiple stocks hitting daily limit-ups. Analysts say this rally may be more durable than previous ones, driven by strong interim results and global expansion. BeiGene's positive results contribute to the sector resonance, attracting capital inflows.
This explains the broader market sentiment and capital rotation into pharma that is lifting BeiGene's stock alongside its own strong results.
New Collaboration with Revolution Medicines Adds Pipeline Potential On August 10, BeiGene announced a collaboration with Revolution Medicines, part of a wave of Chinese pharma global expansion deals. This partnership could bring new pipeline assets and validates BeiGene's research capabilities, offering a potential future growth driver.
This is a new strategic development that could enhance BeiGene's long-term pipeline and global reach, positively impacting investor sentiment.

July 202620 Jun – 23 Jul 2026

▲4

BeiGene's BRUKINSA Data and US Expansion Drive Growth

BRUKINSA Phase 3 Wins in Two Blood Cancers New Phase 3 data show BRUKINSA helps patients live longer without their cancer worsening in two types of blood cancer. This strengthens its position as a top treatment, supporting future sales growth and making the stock more attractive.
These clinical wins directly boost confidence in BeiGene's key drug and future revenue.
BeiGene Achieves First Full-Year Profit BeiGene reached its first full-year profit, a major milestone that shows the company is now financially sustainable. This attracts investors who previously worried about losses and supports a higher stock price.
Profitability is a fundamental shift that improves the investment case.
US Manufacturing Expansion to Avoid Tariffs BeiGene is investing an extra $300 million to expand its US factory, which will make drugs locally and help avoid a potential 100% tariff on imported medicines. This protects profits and ensures supply for the important US market.
This move reduces regulatory and cost risks, directly supporting future earnings.
Zanubrutinib Sales Soar to $3.9 Billion BeiGene's main drug, zanubrutinib, saw global sales jump from $1 billion to $3.9 billion, with most revenue from the US. This proves strong demand and successful commercialization, driving the stock higher.
Strong sales growth is a direct driver of revenue and investor confidence.

20 Jun – 23 Jul 2026

▲4

BeiGene's BRUKINSA Data and US Expansion Drive Growth

BRUKINSA Phase 3 Wins in Two Blood Cancers New Phase 3 data show BRUKINSA helps patients live longer without their cancer worsening in two types of blood cancer. This strengthens its position as a top treatment, supporting future sales growth and making the stock more attractive.
These clinical wins directly boost confidence in BeiGene's key drug and future revenue.
BeiGene Achieves First Full-Year Profit BeiGene reached its first full-year profit, a major milestone that shows the company is now financially sustainable. This attracts investors who previously worried about losses and supports a higher stock price.
Profitability is a fundamental shift that improves the investment case.
US Manufacturing Expansion to Avoid Tariffs BeiGene is investing an extra $300 million to expand its US factory, which will make drugs locally and help avoid a potential 100% tariff on imported medicines. This protects profits and ensures supply for the important US market.
This move reduces regulatory and cost risks, directly supporting future earnings.
Zanubrutinib Sales Soar to $3.9 Billion BeiGene's main drug, zanubrutinib, saw global sales jump from $1 billion to $3.9 billion, with most revenue from the US. This proves strong demand and successful commercialization, driving the stock higher.
Strong sales growth is a direct driver of revenue and investor confidence.